All Oncology News

Venetoclax plus obinutuzumab with or without ibrutinib significantly improved PFS vs chemoimmunotherapy and vs venetoclax plus rituximab in frontline CLL.

Eric Vallieres, MD, FRCSC, discusses the evolving role of surgery in lung cancer treatment following the implementation of new neoadjuvant and adjuvant treatments.

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

Decreases in variant allele frequency in ctDNA were linked to improved CBR with imlunestrant in estrogen receptor–positive, HER2-negative breast cancer

A case study details the importance of genomic testing in identifying cancer and guiding targeted treatment decisions that enhance overall survival.

Next generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.

Eric Winer, MD, discusses the safety and efficacy outcomes of the TakeAim Leukemia trial and future research with emavusertib in combination therapies.

Versamune HPV in combination with pembrolizumab produced a durable median overall survival in patients with recurrent or metastatic HPV16-positive HNSCC.

Frontline toripalimab plus bevacizumab improved progression-free survival and overall survival vs sorafenib in patients with advanced hepatocellular carcinoma.

Hypofractionation radiotherapy was noninferior to conventional fractionation radiotherapy for the treatment of patients with low-risk prostate cancer.

Talquetamab proved safe and effective for relapsed/refractory myeloma, even in patients with comorbidities.

Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.

Kathleen A. Dorritie, MD, discusses long-term data from trials in chronic lymphocytic leukemia presented at the 2023 ASH Annual Meeting.

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as future directions for rivoceranib plus camrelizumab in unresectable HCC.

A study from researchers at Temple University Hospital and Fox Chase Cancer Center found that adjuvant therapy may be underutilized in T2N0 rectal cancer.

UV1 added to pembrolizumab elicited sustained OS outcomes as frontline therapy in advanced, unresectable, or metastatic malignant melanoma.

Benjamin L. Maughan, MD, PharmD, highlights ongoing research regarding the role of cytoreductive nephrectomy and targeted therapies in RCC.

Brittany Bychkovsky, MD, MSc, discusses the role of genetic testing in breast cancer care and explores approaches to improving the testing process.

Enrollment of patients in a phase 2 study evaluating SLS009 in relapsed/refractory AML has been completed and the agent demonstrated initial efficacy.

SL-172154 has been granted orphan drug designation from the FDA in acute myeloid leukemia.

To improve access to lung cancer screening, Roswell Park Comprehensive Cancer Center experts have launched an online provider registry.

The European Commission has approved alectinib for adjuvant use in adult patients with ALK+ non–small cell lung cancer at high risk of recurrence.

China’s National Medical Products Administration has accepted the biologics license application for zanidatamab in second-line HER2+ biliary tract cancer.

The FDA has granted priority review to the supplemental NDA seeking the approval of osimertinib in EGFR-mutated stage III non–small cell lung cancer.

David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances.

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

A case study showed community oncology practices emerged as the preferred site of service for cancer treatment.

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.